About FARCO-PHARMA
FARCO-PHARMA is a company based in Koln (Germany) founded in 1964. It operates as a B2B. FARCO-PHARMA has completed 1 acquisition, including Purenum. FARCO-PHARMA offers products and services including Instillagel, Hydrogel-Methode, VESOXX, Farco-fill, and Deflux. FARCO-PHARMA operates in a competitive market with competitors including Lipella, TheraVida, Esprit Pharma, Regenfro Co and Kissei Pharmaceutical, among others.
- Headquarter Koln, Germany
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Farco-Pharma Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of FARCO-PHARMA
FARCO-PHARMA offers a comprehensive portfolio of products and services, including Instillagel, Hydrogel-Methode, VESOXX, Farco-fill, and Deflux.
Sterile lubricant for urological procedures and examinations
Hydrogel-based treatment for urological conditions
Solution for managing urological issues
Injection solution for medical applications
Injection for urological treatments
Funding Insights of FARCO-PHARMA
Detailed funding history for FARCO-PHARMA
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by FARCO-PHARMA
FARCO-PHARMA has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Purenum.
Investment portfolio details for FARCO-PHARMA
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Biocompatible adhesives for kidney stone fragment removal are developed.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for FARCO-PHARMA
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - FARCO-PHARMA
Detailed financials for FARCO-PHARMA
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Farco-Pharma Comparisons
Peer comparison for FARCO-PHARMA
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of FARCO-PHARMA
FARCO-PHARMA operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lipella, TheraVida, Esprit Pharma, Regenfro Co and Kissei Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Lipid-based therapies for common bladder syndromes are developed.
|
|
| Locked | Locked | Locked |
Clinical stage biopharma company developing drugs for urology and central nervous system disorders
|
|
| Locked | Locked | Locked |
Develop drugs for genitourinary (GU) disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat renal diseases
|
|
| Locked | Locked | Locked |
Therapies for renal diseases and urology-related anemia are developed.
|
|
| Locked | Locked | Locked |
Develops pharmaceuticals for urology, hormone replacement therapy, and female sexual dysfunction treatments.
|
Detailed competitors of FARCO-PHARMA
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Farco-Pharma
Complete news archive for FARCO-PHARMA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about FARCO-PHARMA
FARCO-PHARMA was founded in 1964.
FARCO-PHARMA is headquartered in Koln, Germany. It is registered at Koln, North Rhine-westphalia, Germany.
FARCO-PHARMA GmbH specializes in manufacturing and supplying sterile lubricants, instillation therapies, and medical devices for urological procedures. Based in Germany, they focus on quality products like Instillagel and Hydrogel-Methode, serving healthcare providers and patients through distribution networks. The company engages in events, educational resources, and global partnerships to support urological care and innovation.
FARCO-PHARMA's top competitors include Lipella, Kissei Pharmaceutical and Regenfro Co.
FARCO-PHARMA offers Instillagel, Hydrogel-Methode, VESOXX, Farco-fill, and Deflux.
FARCO-PHARMA has made 1 acquisition, including Purenum.